Neuroone Med Technologies Corp Stock Price, News & Analysis

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC), a medical technology company specializing in neurological disorder treatments, will announce its fiscal second quarter 2025 financial results on May 13, 2025, before market open. The company will host an investor conference call and webcast at 8:30 a.m. Eastern time the same day.

Management will discuss Q2 financial results, provide corporate updates, and hold a Q&A session. The conference call can be accessed via U.S. toll-free number (888-506-0062) or international number (973-528-0011) using participant code 655933. A playback will be available until May 27, 2025, through domestic (877-481-4010) and international (919-882-2331) numbers with replay passcode 52404.

NeuroOne Medical Technologies (Nasdaq: NMTC) has submitted a 510(k) application to the FDA for its OneRF® Trigeminal Nerve Ablation System, ahead of schedule. The system aims to treat trigeminal neuralgia, a chronic facial pain condition affecting approximately 100,000 Americans.

The technology features a minimally invasive surgical procedure using radiofrequency energy to destroy abnormal tissue. Key features include multi-point mapping of pain location, stimulation, and temperature-controlled ablation, all using the same electrode. Published data indicates RF ablation achieves ~95% initial pain relief rates with long-term efficacy and low complication rates.

If FDA cleared, NeuroOne anticipates potential revenue generation from trigeminal nerve ablation by late 2025. The system builds upon the company's FDA-cleared OneRF sEEG Ablation System for brain procedures.

NeuroOne Medical Technologies (NMTC) has issued a shareholder letter highlighting recent achievements and future outlook. The company expanded its partnership with Zimmer Biomet, securing exclusive distribution rights for the OneRF® Ablation System with a $3.0 million upfront payment in November 2024.

The company recently raised $8.3 million from institutional investors, ensuring funding through fiscal 2026. NeuroOne confirmed no material impact from global tariffs due to its US-based supply chain. They plan to submit a 510(k) filing to FDA in May 2025 for trigeminal nerve ablation treatment.

For fiscal year 2025, NeuroOne projects product revenues of $8.0-$10.0 million (132%-190% increase from $3.5 million in FY2024) and improved gross margins of 47%-51% (up from 31% in FY2024). The company is also advancing its Spinal Cord Stimulation Program and sEEG-Based Drug Delivery Program, with strategic partnership discussions underway.

NeuroOne Medical Technologies (Nasdaq: NMTC) announced that its OneRF® Ablation System was featured in a national Fox News article highlighting a successful pediatric epilepsy treatment. The article showcases 17-year-old Clara Fuller, who previously experienced up to 10 seizures nightly due to a rare, medication-resistant epilepsy.

Clara made history as the first pediatric patient treated with NeuroOne's OneRF® technology, which performs minimally invasive radiofrequency ablation of seizure-causing brain tissue. Following the procedure, Clara has become completely seizure-free, enabling her to sleep uninterrupted and resume normal teenage activities.

NeuroOne Medical Technologies (NMTC) has announced the pricing of an underwritten public offering of 16,000,000 shares of common stock at $0.50 per share, aiming to raise $8.0 million in gross proceeds.

The company has granted the underwriter, Ladenburg Thalmann & Co. Inc., a 45-day option to purchase up to an additional 2,400,000 shares at the public offering price less underwriting discount. The offering is expected to close around April 7, 2025.

The net proceeds will be used for general working capital purposes. The shares will be issued under a shelf registration statement on Form S-3 that was declared effective by the SEC on August 16, 2024.

NeuroOne Medical Technologies (NMTC), a medical technology company focused on neurological disorder surgical care, has announced a proposed underwritten registered public offering of common stock shares. The company plans to grant the underwriter a 45-day option to purchase up to an additional 15% of the offered shares.

Ladenburg Thalmann & Co. Inc. will serve as the sole book-running manager for this offering, which will be conducted under an effective shelf registration statement on Form S-3. The offering's completion, size, and terms are subject to market conditions, with no guarantees of successful execution.

The shares will be available through a preliminary prospectus supplement and accompanying prospectus to be filed with the SEC. The offering will only proceed in jurisdictions where it complies with securities laws and registration requirements.

NeuroOne Medical Technologies (Nasdaq: NMTC) CEO Dave Rosa appeared on Today's Marketplace alongside Dr. Jessica Clark to discuss advancements in epilepsy treatment and the company's OneRF® Ablation System. The system, which is the first and only FDA 510(k)-cleared device of its kind, combines the ability to record brain activity and perform RF ablation using a single device.

The OneRF® system consists of three main components: an electrode for stimulation, recording, and ablation; a temperature probe; and a radio frequency heat generator system. This innovation addresses a significant medical need, as over 50 million people worldwide suffer from epilepsy, with approximately one-third of patients experiencing medication-resistant seizures.

NeuroOne Medical Technologies (Nasdaq: NMTC) CEO Dave Rosa appeared on Today's Marketplace to discuss epilepsy treatment innovations alongside Dr. Jessica Clark from Creighton University. The discussion centered on the company's OneRF® Ablation System, which is the first and only FDA 510(k)-cleared device that can both record brain activity and perform RF ablation using the same device.

The system consists of three main components: an electrode for stimulation, recording, and monitoring brain activity with ablation capability, a temperature probe, and a radio frequency heat generator system. This innovation addresses a critical need, as over 50 million people worldwide suffer from epilepsy, with approximately one-third of patients experiencing medication-resistant seizures.

NeuroOne Medical Technologies (Nasdaq: NMTC) has accelerated its FDA 510(k) submission timeline for the OneRF® Trigeminal Nerve Ablation System to May 2025, approximately two months ahead of the original schedule. The system aims to treat facial pain caused by trigeminal neuralgia through minimally invasive radiofrequency ablation.

This represents the company's second radiofrequency ablation technology utilizing their patented OneRF® Technology Platform. According to Research and Markets, the trigeminal neuralgia therapeutics market is projected to grow from $262 million in 2024 to $416 million by 2030, driven by an aging population.

If FDA cleared, NeuroOne anticipates potential revenue generation from trigeminal nerve ablation in late 2025, which wasn't previously expected within the 2025 calendar year. This would add to their portfolio of three FDA-cleared product families.